Curevac NV 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
CVAC
Curevac NVCureVac restructures its collaboration with GSK into a licensing agreement, granting GSK full control over influenza and COVID-19 vaccine development while CureVac focuses on oncology and other areas.
CVAC
Curevac NV20-F: CureVac Amends Long-Term Incentive Plan and Discloses Key Financial, Legal, and Governance Details
CureVac updates its long-term incentive plan, discloses key financial metrics, and addresses legal and corporate governance matters in its latest filing.